K Smith1,2, J Winstanley3, F Boyle3, A O'Reilly3, M White4,5, Y C Antill4. 1. Cabrini Hospital, Medical Oncology, Melbourne, Australia. kortnye.smith@petermac.org. 2. Peter MacCallum Cancer Centre, Medical Oncology, 305 Grattan St, Melbourne, VIC, 3000, Australia. kortnye.smith@petermac.org. 3. Patricia Ritchie Centre for Cancer Care and Research, University of Sydney-The Mater Hospital, Medical Oncology, Sydney, Australia. 4. Cabrini Hospital, Medical Oncology, Melbourne, Australia. 5. Monash Medical Centre, Medical Oncology, Melbourne, Australia.
Abstract
PURPOSE: Eyebrow and eyelash loss (madarosis) is a common and distressing side effect of chemotherapy for which no protective strategies have yet been developed. The purpose of this study was to develop an overview of perceptions and experiences of women undergoing taxane-based treatment for early breast cancer. METHODS: A total of 25 women with a diagnosis of invasive early breast cancer participated in a focus group (n = 5), ages ranging from 35 to 64 (median 50), all had completed therapy with a taxane-based chemotherapy treatment. This focus group used targeted questions to explore participants' perceptions and experience of madarosis during and following chemotherapy and identified issues associated with impact of madarosis on quality of life (QoL). Thematic analysis was conducted to identify important issues experienced by participants. RESULTS: Seven themes emerged from the data: (1) timing of regrowth and permanent changes, (2) meaning/importance of eyebrow/eyelashes, (3) preparedness/information given, (4) impact of the hair loss of self, (5) impact of hair loss on others, (6) physiological side effects of loss of eyebrows/eyelashes, and (7) management of loss of eyebrows/eyelashes. In addition, participants noted physical symptoms of eye irritation during their treatment that they attributed to madarosis. CONCLUSION: This study highlights the significant impact of madarosis on patients, providing the first published analysis of patient's attitude and perception of eyelash and eyebrow loss during chemotherapy. Further research in this area is required and will be benefitted from the development of a dedicated instrument/questionnaire that can capture and measure the impact of madarosis on QoL and allow development of clinical trial strategies.
PURPOSE: Eyebrow and eyelash loss (madarosis) is a common and distressing side effect of chemotherapy for which no protective strategies have yet been developed. The purpose of this study was to develop an overview of perceptions and experiences of women undergoing taxane-based treatment for early breast cancer. METHODS: A total of 25 women with a diagnosis of invasive early breast cancer participated in a focus group (n = 5), ages ranging from 35 to 64 (median 50), all had completed therapy with a taxane-based chemotherapy treatment. This focus group used targeted questions to explore participants' perceptions and experience of madarosis during and following chemotherapy and identified issues associated with impact of madarosis on quality of life (QoL). Thematic analysis was conducted to identify important issues experienced by participants. RESULTS: Seven themes emerged from the data: (1) timing of regrowth and permanent changes, (2) meaning/importance of eyebrow/eyelashes, (3) preparedness/information given, (4) impact of the hair loss of self, (5) impact of hair loss on others, (6) physiological side effects of loss of eyebrows/eyelashes, and (7) management of loss of eyebrows/eyelashes. In addition, participants noted physical symptoms of eye irritation during their treatment that they attributed to madarosis. CONCLUSION: This study highlights the significant impact of madarosis on patients, providing the first published analysis of patient's attitude and perception of eyelash and eyebrow loss during chemotherapy. Further research in this area is required and will be benefitted from the development of a dedicated instrument/questionnaire that can capture and measure the impact of madarosis on QoL and allow development of clinical trial strategies.
Entities:
Keywords:
Alopecia; Breast cancer; Hair loss; Madarosis; Quality of life; Questionnaire development
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: C Paterson; M Kozlovskaia; M Turner; K Strickland; C Roberts; R Ogilvie; G Pranavan; P Craft Journal: J Cancer Surviv Date: 2020-07-18 Impact factor: 4.442
Authors: Azael Freites-Martinez; Jerry Shapiro; Corina van den Hurk; Shari Goldfarb; Joaquin J Jimenez; Anthony M Rossi; Ralf Paus; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2018-04-14 Impact factor: 11.527
Authors: Anne Versluis; Kirsten van Alphen; Wouter Dercksen; Henk de Haas; Corina van den Hurk; Ad A Kaptein Journal: Support Care Cancer Date: 2022-01-20 Impact factor: 3.603
Authors: Kirsten van Alphen; Anne Versluis; Wouter Dercksen; Henk de Haas; Rieneke Lugtenberg; Jitske Tiemensma; Judith Kroep; Elizabeth Broadbent; Ad A Kaptein; Corina van den Hurk Journal: Asia Pac J Oncol Nurs Date: 2020-03-30